Antibody-drug conjugates in gynecologic oncology

Antibody-drug conjugates (ADCs) have profoundly changed gynecological oncology in a very short space of time. Within just two years, three ADCs – mirvetuximab soravtansine, tisotumab vedotin and trastuzumab deruxtecan – have been approved for gynecological tumors in ovarian, cervical and all solid HER2-positive tumors, including endometrial and ovarian cancer. The final survival analysis of the MIRASOL trial (SGO 2025) and the full approval of tisotumab vedotin (April 2024) consolidate the position of this substance class.